Krystal Biotech (KRYS) News Today $192.30 -2.14 (-1.10%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$192.30 -0.01 (0.00%) As of 03/25/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Segall Bryant & Hamill LLC Has $23.39 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS)Segall Bryant & Hamill LLC cut its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 149,309 shares of theMarch 26 at 5:41 AM | marketbeat.comSummit Global Investments Acquires New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS)Summit Global Investments bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,453 shares of the company's stock, valued at approximaMarch 25 at 4:21 AM | marketbeat.comCibc World Markets Corp Invests $364,000 in Krystal Biotech, Inc. (NASDAQ:KRYS)Cibc World Markets Corp acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,321 shares of the company's stock, valued at approximately $364,000. SMarch 25 at 3:53 AM | marketbeat.comStocks Showing Improving Market Leadership: Metsera Earns 82 RS RatingMarch 24 at 1:32 PM | msn.comSwiss National Bank Increases Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)Swiss National Bank grew its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 8.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 42,400 shares of the company's stock after purchasing an additionalMarch 23 at 3:35 AM | marketbeat.comCorient Private Wealth LLC Reduces Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)Corient Private Wealth LLC cut its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 43,009 shares of the company's stock after selling 4,678 shares during the period. CorMarch 22, 2025 | marketbeat.comShort Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Decreases By 13.5%March 21, 2025 | americanbankingnews.comZurcher Kantonalbank Zurich Cantonalbank Raises Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 31.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 6,054 shares of the company's stock after acquiring an additional 1,44March 21, 2025 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Down 13.5% in FebruaryKrystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 2,760,000 shares, a decline of 13.5% from the February 13th total of 3,190,000 shares. Currently, 11.2% of the company's stock are short sold. Based on an average daily trading volume, of 278,600 shares, the short-interest ratio is currently 9.9 days.March 20, 2025 | marketbeat.comPrivium Fund Management B.V. Buys 2,900 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)Privium Fund Management B.V. boosted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 45.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,250 shares of the company's stockMarch 20, 2025 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Receives $220.00 Consensus Target Price from BrokeragesMarch 20, 2025 | americanbankingnews.comHarrow Shows Market Leadership With Jump To 92 RS RatingMarch 19, 2025 | msn.comRaymond James Financial Inc. Takes $15.99 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS)Raymond James Financial Inc. bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 102,061 shares of the company's stock, valued at approximately $15,989,000. RaymonMarch 19, 2025 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Rating of "Buy" from AnalystsKrystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has been given an average rating of "Buy" by the eight brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a stronMarch 17, 2025 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Skandinaviska Enskilda Banken AB publSkandinaviska Enskilda Banken AB publ lowered its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 29.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 89,047 shares of the company's stock after selling 37,035 shares duringMarch 16, 2025 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Position Increased by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lifted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 1.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 243,170 shareMarch 16, 2025 | marketbeat.comInsider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 25,000 Shares of StockKrystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.March 14, 2025 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Lifted by AlphaQuest LLCAlphaQuest LLC lifted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 116.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,020 shares of the company's stock after purchasing an additional 1,622 shareMarch 13, 2025 | marketbeat.comVictory Capital Management Inc. Reduces Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)Victory Capital Management Inc. cut its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 17.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 81,328 shares of the company's stock after sMarch 13, 2025 | marketbeat.comWilliam Blair Sticks to Their Hold Rating for Legend Biotech (LEGN)March 12, 2025 | markets.businessinsider.comBank of New York Mellon Corp Has $26.53 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS)Bank of New York Mellon Corp lessened its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 1.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 169,346 shares of the company's stock after selling 2,307 shares during theMarch 10, 2025 | marketbeat.comEdgestream Partners L.P. Sells 8,447 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)Edgestream Partners L.P. lessened its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 26.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 23,810 shares of the company's stock after selling 8,447 shares during the period. Edgestream PartMarch 9, 2025 | marketbeat.comKrystal Biotech at TD Cowen Conference: Strategic Pipeline ProgressMarch 8, 2025 | uk.investing.comKrystal Biotech (NASDAQ:KRYS) Coverage Initiated at Jefferies Financial GroupJefferies Financial Group started coverage on Krystal Biotech in a research report on Wednesday. They set a "buy" rating and a $245.00 price target on the stock.March 6, 2025 | marketbeat.comJefferies Initiates Coverage of Krystal Biotech (KRYS) with Buy RecommendationMarch 5, 2025 | msn.comKrystal Biotech initiated at buy at Jefferies on Vyjuvek, gene delivery techMarch 5, 2025 | msn.comKrystal Biotech initiated with a Buy at JefferiesMarch 5, 2025 | markets.businessinsider.comIs the Market Bullish or Bearish on Krystal Biotech?March 4, 2025 | benzinga.comKrystal Biotech's (KRYS) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Friday.March 1, 2025 | marketbeat.comA Closer Look At Krystal Biotech's EarningsMarch 1, 2025 | finance.yahoo.comKrystal gets positive EU regulatory opinion for VyjuvekMarch 1, 2025 | seekingalpha.comKrystal Biotech, Inc. (NASDAQ:KRYS) CAO Kathryn Romano Sells 750 SharesMarch 1, 2025 | insidertrades.comKathryn Romano Sells 750 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) StockKrystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.March 1, 2025 | marketbeat.comNew York State Common Retirement Fund Has $3.66 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)New York State Common Retirement Fund lowered its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 23,382 shares of the company's stock afterMarch 1, 2025 | marketbeat.comKrystal Biotech Gets CHMP Backing for Vyjuvek ApprovalFebruary 28, 2025 | marketwatch.comKrystal Biotech receives positive CHMP opinion for VYJUVEKFebruary 28, 2025 | markets.businessinsider.comKrystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis BullosaFebruary 28, 2025 | globenewswire.comIllinois Municipal Retirement Fund Buys 1,505 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)Illinois Municipal Retirement Fund increased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 11.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,146 shareFebruary 28, 2025 | marketbeat.comKrystal Biotech to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | markets.businessinsider.comKrystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Raised by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D lifted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 19.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,803 shares of the company's stock afFebruary 26, 2025 | marketbeat.comPrincipal Financial Group Inc. Boosts Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)Principal Financial Group Inc. lifted its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 3.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 123,453 shares of the company's stock after purchaFebruary 25, 2025 | marketbeat.comC WorldWide Group Holding A S Reduces Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)C WorldWide Group Holding A S decreased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 22.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 105,809 shares of the company's stock after selling 30,000 shares during the quaFebruary 24, 2025 | marketbeat.comBrokers Issue Forecasts for Krystal Biotech FY2026 EarningsKrystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Chardan Capital issued their FY2026 EPS estimates for shares of Krystal Biotech in a report issued on Thursday, February 20th. Chardan Capital analyst Y. Livshits anticipates that the company will post earnings per share of $9.95 for the year. CFebruary 24, 2025 | marketbeat.comCantor Fitzgerald Weighs in on Krystal Biotech FY2025 EarningsKrystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Krystal Biotech in a research report issued to clients and investors on Thursday, February 20th. Cantor Fitzgerald analyst J. Schimmer anticipates that theFebruary 24, 2025 | marketbeat.comBrokers Offer Predictions for Krystal Biotech Q1 EarningsKrystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Krystal Biotech in a note issued to investors on Wednesday, February 19th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings pFebruary 24, 2025 | marketbeat.comWilliam Blair Raises Earnings Estimates for Krystal BiotechKrystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Stock analysts at William Blair upped their Q1 2025 earnings per share estimates for shares of Krystal Biotech in a research note issued on Wednesday, February 19th. William Blair analyst S. Corwin now forecasts that the company will post earninFebruary 24, 2025 | marketbeat.comWilliam Blair Comments on Krystal Biotech Q1 EarningsKrystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Krystal Biotech in a research note issued to investors on Wednesday, February 19th. William Blair analyst S. Corwin expects that the compFebruary 22, 2025 | marketbeat.comHussman Strategic Advisors Inc. Takes $658,000 Position in Krystal Biotech, Inc. (NASDAQ:KRYS)Hussman Strategic Advisors Inc. purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 4,200 shares of the company's stock, valued at approxFebruary 22, 2025 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Handelsbanken Fonder ABHandelsbanken Fonder AB cut its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 85,300 shares of the companyFebruary 22, 2025 | marketbeat.comKrystal Biotech (NASDAQ:KRYS) Given New $215.00 Price Target at CitigroupCitigroup lifted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday.February 21, 2025 | marketbeat.com Remove Ads Get Krystal Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter. Email Address KRYS Media Mentions By Week KRYS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KRYS News Sentiment▼1.320.79▲Average Medical News Sentiment KRYS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KRYS Articles This Week▼146▲KRYS Articles Average Week Remove Ads Get Krystal Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TEVA News SMMT News ITCI News MRNA News GMAB News RDY News VTRS News ASND News PCVX News QGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KRYS) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
